Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
KmXQ2tWnL1sLHzJa
